525 related articles for article (PubMed ID: 28967645)
1. Association of CD44
Chekhun VF; Lukianova NY; Chekhun SV; Bezdieniezhnykh NO; Zadvorniy TV; Borikun TV; Polishchuk LZ; Klyusov OМ
Exp Oncol; 2017 Sep; 39(3):203-211. PubMed ID: 28967645
[TBL] [Abstract][Full Text] [Related]
2. Are CD44
Ryspayeva DE; Smolanka II; Dudnichenko АS; Lyashenko AA; Grinevich YA; Gurianov VG; Koshubarova MV; Seleznev AA
Exp Oncol; 2017 Sep; 39(3):224-228. PubMed ID: 28967636
[TBL] [Abstract][Full Text] [Related]
3. Effect of curcumin on the cell surface markers CD44 and CD24 in breast cancer.
Calaf GM; Ponce-Cusi R; Abarca-Quinones J
Oncol Rep; 2018 Jun; 39(6):2741-2748. PubMed ID: 29693159
[TBL] [Abstract][Full Text] [Related]
4. СD44+/CD24- markers of cancer stem cells in patients with breast cancer of different molecular subtypes.
Chekhun SV; Zadvorny TV; Tymovska YO; Anikusko MF; Novak OE; Polishchuk LZ
Exp Oncol; 2015 Mar; 37(1):58-63. PubMed ID: 25804234
[TBL] [Abstract][Full Text] [Related]
5. SLUG/SNAI2 and tumor necrosis factor generate breast cells with CD44+/CD24- phenotype.
Bhat-Nakshatri P; Appaiah H; Ballas C; Pick-Franke P; Goulet R; Badve S; Srour EF; Nakshatri H
BMC Cancer; 2010 Aug; 10():411. PubMed ID: 20691079
[TBL] [Abstract][Full Text] [Related]
6. A CD44⁻/CD24⁺ phenotype is a poor prognostic marker in early invasive breast cancer.
Ahmed MA; Aleskandarany MA; Rakha EA; Moustafa RZ; Benhasouna A; Nolan C; Green AR; Ilyas M; Ellis IO
Breast Cancer Res Treat; 2012 Jun; 133(3):979-95. PubMed ID: 22119938
[TBL] [Abstract][Full Text] [Related]
7. Unraveling the roles of CD44/CD24 and ALDH1 as cancer stem cell markers in tumorigenesis and metastasis.
Li W; Ma H; Zhang J; Zhu L; Wang C; Yang Y
Sci Rep; 2017 Oct; 7(1):13856. PubMed ID: 29062075
[TBL] [Abstract][Full Text] [Related]
8. STAT3 as a promising chemoresistance biomarker associated with the CD44
Moreira MP; da Conceição Braga L; Cassali GD; Silva LM
Exp Cell Res; 2018 Feb; 363(2):283-290. PubMed ID: 29352988
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of Cdk2 kinase activity selectively targets the CD44⁺/CD24⁻/Low stem-like subpopulation and restores chemosensitivity of SUM149PT triple-negative breast cancer cells.
Opyrchal M; Salisbury JL; Iankov I; Goetz MP; McCubrey J; Gambino MW; Malatino L; Puccia G; Ingle JN; Galanis E; D'Assoro AB
Int J Oncol; 2014 Sep; 45(3):1193-9. PubMed ID: 24970653
[TBL] [Abstract][Full Text] [Related]
10. A small-molecule inhibitor of SMAD3 attenuates resistance to anti-HER2 drugs in HER2-positive breast cancer cells.
Chihara Y; Shimoda M; Hori A; Ohara A; Naoi Y; Ikeda JI; Kagara N; Tanei T; Shimomura A; Shimazu K; Kim SJ; Noguchi S
Breast Cancer Res Treat; 2017 Nov; 166(1):55-68. PubMed ID: 28702892
[TBL] [Abstract][Full Text] [Related]
11. CD44/CD24 as potential prognostic markers in node-positive invasive ductal breast cancer patients treated with adjuvant chemotherapy.
Adamczyk A; Niemiec JA; Ambicka A; Mucha-Małecka A; Mituś J; Ryś J
J Mol Histol; 2014 Feb; 45(1):35-45. PubMed ID: 23835592
[TBL] [Abstract][Full Text] [Related]
12. The CD44+/CD24- phenotype is enriched in basal-like breast tumors.
Honeth G; Bendahl PO; Ringnér M; Saal LH; Gruvberger-Saal SK; Lövgren K; Grabau D; Fernö M; Borg A; Hegardt C
Breast Cancer Res; 2008; 10(3):R53. PubMed ID: 18559090
[TBL] [Abstract][Full Text] [Related]
13. The role of CD44+/CD24-/low biomarker for screening, diagnosis and monitoring of breast cancer.
Camerlingo R; Ferraro GA; De Francesco F; Romano M; Nicoletti G; Di Bonito M; Rinaldo M; D'Andrea F; Pirozzi G
Oncol Rep; 2014 Mar; 31(3):1127-32. PubMed ID: 24366074
[TBL] [Abstract][Full Text] [Related]
14. Modifying effects of lactoferrin in vitro on molecular phenotype of human breast cancer cells.
Chekhun VF; Zalutskii IV; Naleskina LA; Lukianova NY; Yalovenko TM; Borikun TV; Sobchenko SO; Semak IV; Lukashevich VS
Exp Oncol; 2015 Sep; 37(3):181-6. PubMed ID: 26422101
[TBL] [Abstract][Full Text] [Related]
15. In situ identification of CD44+/CD24- cancer cells in primary human breast carcinomas.
Perrone G; Gaeta LM; Zagami M; Nasorri F; Coppola R; Borzomati D; Bartolozzi F; Altomare V; Trodella L; Tonini G; Santini D; Cavani A; Muda AO
PLoS One; 2012; 7(9):e43110. PubMed ID: 23028444
[TBL] [Abstract][Full Text] [Related]
16. Metformin-induced preferential killing of breast cancer initiating CD44+CD24-/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts.
Cufi S; Corominas-Faja B; Vazquez-Martin A; Oliveras-Ferraros C; Dorca J; Bosch-Barrera J; Martin-Castillo B; Menendez JA
Oncotarget; 2012 Apr; 3(4):395-8. PubMed ID: 22565037
[TBL] [Abstract][Full Text] [Related]
17. Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristics.
Calcagno AM; Salcido CD; Gillet JP; Wu CP; Fostel JM; Mumau MD; Gottesman MM; Varticovski L; Ambudkar SV
J Natl Cancer Inst; 2010 Nov; 102(21):1637-52. PubMed ID: 20935265
[TBL] [Abstract][Full Text] [Related]
18. Microenvironmental networks promote tumor heterogeneity and enrich for metastatic cancer stem-like cells in Luminal-A breast tumor cells.
Weitzenfeld P; Meshel T; Ben-Baruch A
Oncotarget; 2016 Dec; 7(49):81123-81143. PubMed ID: 27835603
[TBL] [Abstract][Full Text] [Related]
19. Molecular iodine impairs chemoresistance mechanisms, enhances doxorubicin retention and induces downregulation of the CD44+/CD24+ and E-cadherin+/vimentin+ subpopulations in MCF-7 cells resistant to low doses of doxorubicin.
Bontempo A; Ugalde-Villanueva B; Delgado-González E; Rodríguez ÁL; Aceves C
Oncol Rep; 2017 Nov; 38(5):2867-2876. PubMed ID: 28901484
[TBL] [Abstract][Full Text] [Related]
20. Predictive value of CD44 and CD24 for prognosis and chemotherapy response in invasive breast ductal carcinoma.
Chen Y; Song J; Jiang Y; Yu C; Ma Z
Int J Clin Exp Pathol; 2015; 8(9):11287-95. PubMed ID: 26617852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]